Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.
OBJECTIVE
Lafutidine is a novel H(2)-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7- or 14-day lafutidine-clarithromycin-amoxicillin therapy versus a lansoprazole-based regimen for Helicobacter pylori eradication.


METHODS
Four hundred and sixty-three patients with H. pylori-infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared.


RESULTS
The eradication rates by the intention-to-treat and per-protocol analyses in the 7LFT and 7LPZ groups were 76.5% and 81.6%, and 76.9% and 82.0% (p = .94 and .95), respectively. The eradication rates by intention-to-treat and per-protocol analyses in the 14LFT and 14LPZ groups were 78.2% and 82.2%, and 80.4% and 85.9% (p = .70 and .49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups.


CONCLUSIONS
The results of this study showed that lafutidine-clarithromycin-amoxicillin therapy was a safe and effective as lansoprazole-based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option.
Kim
Nayoung
N
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Park
Soo-Heon
SH
Seo
Geom Seog
GS
Lee
Sang Woo
SW
Kim
Jae Woo
JW
Lee
Kwang Jae
KJ
Shin
Won-Chang
WC
Kim
Tae Nyeun
TN
Park
Moo-In
MI
Park
Jong-Jae
JJ
Hong
Su Jin
SJ
Shim
Ki-Nam
KN
Kim
Sang Wook
SW
Shin
Yong-Woon
YW
Chang
Young-Woon
YW
Chun
Hoon Jai
HJ
Lee
Ok-Jae
OJ
Jeon
Won-Joong
WJ
Park
Chan-Guk
CG
Cho
Chang-Min
CM
Park
Cheol Hee
CH
Won
Sun Young
SY
Lee
Gin Hyug
GH
Park
Kyung Sik
KS
Shin
Jeong Eun
JE
Kim
Heung Up
HU
Park
Joon Yong
JY
Chae
Hiun Suk
HS
Song
Geun Am
GA
Kim
Jae Gyu
JG
Yoon
Byung Chul
BC
Seol
Sangyong
S
Jung
Hyun Chae
HC
Chung
In-Sik
IS
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000081:Acetamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007723:Korea; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000081:Acetamides; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D010880:Piperidines; D011725:Pyridines; D064747:Lansoprazole; C076948:lafutidine; D000658:Amoxicillin; D017291:Clarithromycin